Sibgat Choudhury
About Sibgat Choudhury
Sibgat Choudhury is the Senior Director of Clinical Biomarker Development at Acrivon Therapeutics, Inc., where he has worked since 2021. He holds a Ph.D. in Experimental Medicine from McGill University and has extensive experience in biomarker development and quality control in the pharmaceutical industry.
Work at Acrivon Therapeutics
Sibgat Choudhury has been with Acrivon Therapeutics, Inc. since 2021. He currently holds the position of Senior Director, Clinical Biomarker Development, a role he has occupied since 2023. Prior to this, he served as Director, Clinical Biomarker Development for two years. Acrivon Therapeutics is located in Watertown, Massachusetts, and focuses on developing innovative therapeutic solutions.
Previous Experience at Metamark Genetics
Before joining Acrivon Therapeutics, Sibgat Choudhury worked at Metamark Genetics. His tenure included roles as Research Scientist from 2012 to 2014, Senior Research Scientist from 2014 to 2015, and Associate Director for a brief period in 2015. His experiences at Metamark Genetics contributed to his expertise in biomarker development.
Background in Pharmaceuticals
Sibgat Choudhury began his career in the pharmaceutical industry at Beximco Pharmaceuticals Ltd. He worked as a Quality Control Officer from 1995 to 1996, then progressed to Senior Quality Control Officer and QC Supervisor from 1996 to 1997. This early experience laid the foundation for his later roles in clinical and biomarker development.
Education and Expertise
Sibgat Choudhury holds a Ph.D. in Experimental Medicine from McGill University, where he studied from 2002 to 2007. He also earned a Master of Science in Biology with a focus on Molecular Biology from Long Island University between 1998 and 2001. Earlier, he completed a Master of Science in Biochemistry at the University of Dhaka from 1992 to 1995. His educational background supports his extensive knowledge in clinical biomarker development.